Management of Chronic Hepatitis B with Positive HBsAg and HBsAb

Introduction to Treatment

Patients with positive HBsAg and positive HBsAb should be treated with high-barrier-to-resistance antiviral therapy, preferably entecavir or tenofovir, to suppress HBV replication and prevent disease progression 1, 2

The American Gastroenterological Association recommends entecavir (0.5-1mg daily) or tenofovir (300mg daily) as the preferred first-line treatments due to their high potency and high barrier to resistance 1, 2
These agents can achieve virological remission (undetectable HBV DNA) in >90% of treatment-adherent patients after 3 years 2
The European Association for the Study of the Liver advises against using lamivudine due to high resistance rates with long-term therapy 3, 4

The primary goal of treatment is to suppress HBV replication to prevent progression to cirrhosis, liver failure, and hepatocellular carcinoma, as recommended by the American Association for the Study of Liver Diseases 5, 1
Secondary goals include normalization of ALT levels 5 and histological improvement 5, 1

The American Gastroenterological Association recommends checking HBV DNA and ALT levels at baseline and every 3-6 months during therapy 6, 3
Monitoring for hepatitis flares (ALT >100 U/mL and 3 times baseline) is crucial 7

Long-term (potentially lifelong) therapy is typically required for HBsAg-positive patients, as recommended by the European Association for the Study of the Liver 1, 2
Treatment should continue until HBsAg loss is achieved and maintained for 6-12 months (ideal but uncommon endpoint) 1

Baseline liver fibrosis assessment (biopsy or non-invasive methods like transient elastography) should be performed to guide treatment decisions and duration, as recommended by the American Association for the Study of Liver Diseases 5, 2
For patients with HBV DNA ≥2000 IU/mL and elevated ALT, treatment is recommended regardless of fibrosis stage 2

The American Gastroenterological Association advises against assuming the presence of HBsAb indicates immunity when HBsAg is also positive, and against using lamivudine as first-line therapy due to high resistance rates (up to 70% after 5 years) 4
Patients should be counseled that treatment is typically long-term and that premature discontinuation can lead to severe hepatitis flares, as recommended by the European Association for the Study of the Liver 5, 1

Even after HBsAg loss, patients should undergo lifelong screening for hepatocellular carcinoma if they had significant fibrosis or cirrhosis at baseline, as recommended by the American Association for the Study of Liver Diseases 1
Regular monitoring of renal function is necessary for patients on tenofovir due to potential nephrotoxicity, as recommended by the American Gastroenterological Association 3